Summary
We describe a method combining immunomagnetic beads and fluorescence-activated cell sorting to isolate and analyze defined immune cell subpopulations of peripheral blood mononuclear cells (monocytes, CD4+ T cells, CD8+ T cells, B cells, and natural killer cells). Using this method, magnetic and fluorescently labeled cells can be purified and analyzed.
Abstract
Infectious mononucleosis (IM) is an acute syndrome mostly associated with primary Epstein–Barr virus (EBV) infection. The main clinical symptoms include irregular fever, lymphadenopathy, and significantly increased lymphocytes in peripheral blood. The pathogenic mechanism of IM is still unclear; there is no effective treatment method for it, with mainly symptomatic therapies being available. The main question in EBV immunobiology is why only a small subset of infected individuals shows severe clinical symptoms and even develop EBV-associated malignancies, whilemost individuals are asymptomatic for life with the virus.
B cells are first involved in IM because EBV receptors are presented on their surface. Natural killer (NK) cells are cytotoxic innate lymphocytes that are important for killing EBV-infected cells. The proportion of CD4+ T cells decreases while that of CD8+ T cells expands dramatically during acute EBV infection, and the persistence of CD8+ T cells is important for lifelong control of IM. Those immune cells play important roles in IM, and their functions need to be identified separately. For this purpose, monocytes are separated first from peripheral blood mononuclear cells (PBMCs) of IM individuals using CD14 microbeads, a column, and a magnetic separator.
The remaining PBMCs are stained with peridinin-chlorophyll-protein (PerCP)/Cyanine 5.5 anti-CD3, allophycocyanin (APC)/Cyanine 7 anti-CD4, phycoerythrin (PE) anti-CD8, fluorescein isothiocyanate (FITC) anti-CD19, APC anti-CD56, and APC anti-CD16 antibodies to sort CD4+ T cells, CD8+ T cells, B cells, and NK cells using a flow cytometer. Furthermore, transcriptome sequencing of five subpopulations was performed to explore their functions and pathogenic mechanisms in IM.
Introduction
Epstein–Barr virus (EBV), a γ-herpesvirus also known as human herpes virus type 4, is ubiquitous in the human population and establishes lifelong latent infection in more than 90% of the adult population1. Most EBV primary infection occurs during childhood and adolescence, with a fraction of patients manifesting with infectious mononucleosis (IM)2, showing characteristic immunopathology, including an activated immune response with CD8+ T cells in blood and a transient proliferation of EBV-infected B cells in the oropharynx3. The course of IM may last for 2–6 weeks and the majority of the patients recover well4. However, some individuals develop persistent or recurrent IM-like symptoms with high morbidity and mortality, which is classified as chronic active EBV infection (CAEBV)5. In addition, EBV is an important oncogenic virus, which is closely related to a variety of malignancies, including epithelioid and lymphoid malignancies such asnasopharyngeal carcinoma, Burkitt's lymphoma, Hodgkin's lymphoma (HL), and T/NK cell lymphoma6. Although EBV has been studied for over 50 years, its pathogenesis and the mechanism by which it induces the proliferation of lymphocytes have not been fully elucidated.
Several studies have investigated the molecular signatures for the immunopathology of EBV infection by transcriptome sequencing. Zhong et al. analyzed whole-transcriptome profiling of peripheral blood mononuclear cells (PBMCs) from Chinese children with IM or CAEBV to find that CD8+ T cell expansion was predominantly found in the IM group7, suggesting that CD8+ T cells may play a major role in IM. Similarly, another study found lower proportions of EBV-specific cytotoxic T and CD19+ B cells and higher percentages of CD8+ T cells in patients with IM caused by primary EBV infection than in patients with IM caused both by EBV reactivation and other agents8. B cells are first involved in IM because EBV receptors are presented on their surface. Al Tabaa et al. found that B cells were polyclonally activated and differentiated intoplasmablasts (CD19+, CD27+ and CD20−, and CD138− cells) and plasma cells (CD19+, CD27+ and CD20−, and CD138+) during IM9. Moreover, Zhong et al. found that monocyte markers CD14 and CD64 were upregulated in CAEBV, suggesting that monocytes may play an important role in the cellular immune response of CAEBV through antibody-dependent cellular cytotoxicity (ADCC) and hyperactive phagocytosis7. Alka et al. characterized the transcriptome of MACS sorted CD56dim CD16+ NK cells from four patients of IM or HL and found that NK cells from both IM and HL had downregulated innate immunity and chemokine signaling genes, which could be responsible for the hyporesponsiveness of NK cells10. In addition, Greenough et al. analyzed gene expression of sorted CD8+ T cells from 10 PBMCs of individuals with IM. They reported that a large proportion of CD8+ T cells in IM were virus-specific, activated, dividing, and primed to exert effector activities11. Both T cell-mediated, EBV-specific responses, and NK cell-mediated, nonspecific responses play essential roles during primary EBV infection. However, these studies only investigated the transcriptome results of the diverse mixture of immune cells or only a certain subpopulation of lymphocytes, which is not sufficient for the comprehensive comparison of the molecular characteristics and functions of different immune cell subpopulations in children with IM at the same disease state.
This paper describes a method that combines immunomagnetic beads and fluorescence-activated cell sorting (FACS) to isolate and analyze defined immune cell subpopulations of PBMCs (monocytes, CD4+ T cells, CD8+ T cells, B cells, and NK cells). Using this method, magnetic and fluorescently labeled cells can be purified using a magnetic separator and FACS or analyzed by flow cytometry. RNA can be extracted from the purified cells for transcriptome sequencing. This method will enable the characterization and gene expression of different immune cells in the same states of disease of individuals with IM, which will expand our understanding of the immunopathology of EBV infection.
Subscription Required. Please recommend JoVE to your librarian.
Protocol
Blood samples were obtained from patients with IM (n = 3), healthy EBV carriers (n = 3), and EBV-uninfected children (n = 3). Volunteers were recruited from Beijing Children's Hospital, Capital Medical University, and all studies were ethically approved. Ethical approval was obtained by the Ethics Committee of Beijing Children's Hospital, Capital Medical University (Approval Number: [2021]-E-056-Y). Informed consent of patients was waived as the study only used the remaining samples for clinical testing. All data were fully deidentified and anonymized to protect patient privacy.
1. Isolation of PBMCs from peripheral blood
- Collect fresh peripheral blood (2 mL) from patients with IM into K3EDTA tubes by standard venipuncture.
NOTE: The process needs to be rapid to maintain cell viability. - Dilute peripheral blood to twofold volume with phosphate-buffered saline (PBS) and layer it on top of human lymphocyte separation medium (density: 1.077 ± 0.001 g/mL) in a 15 mL centrifuge tube.
NOTE: The volume ratio of blood, PBS, and separation medium was 1:1:1. Add the blood slowly to the separation medium, and centrifuge immediately to avoid blood settling into the separation medium. - Centrifuge at 800 × g for 20 min at room temperature. Transfer the middle layer (enriched PBMCs) to another 15 mL centrifuge tube.
NOTE: After centrifugation, at the bottom of the tube are erythrocytes, the middle layer is the separation medium, the top layer is plasma, and between the plasma layer and the separation liquid layer were the PBMCs (including lymphocytes and monocytes). - Wash the PBMCs with 10 mL of PBS and centrifuge at 800 × g for 20 min at room temperature; discard the supernatant carefully.
- Repeat the washing and centrifuging (step 1.4) 2 x. Resuspend the PBMCs with 1 mL of PBS in a 1.5 mL microcentrifuge tube and count the cells with a trypan blue-based, automated counter.
2. Isolation of CD14 + monocytes from PBMCs using CD14 microbeads
- Prepare a buffer solution containing 0.5% fetal bovine serum (FBS) and 2 mM EDTA in PBS (pH 7.2). Keep the buffer cold (2−8 °C).
NOTE: Degas the buffer before use as air bubbles could block the column. Keep the cells cold to prevent capping of the antibodies on the cell surface and non-specific cell labeling. - Centrifuge the PBMCs at 300 × g for 10 min at room temperature. Discard the supernatant carefully. Resuspend the cells with 80 µL of the buffer. Add 20 µL of CD14 microbeads to the cell suspension.
NOTE: If there are ≤107 PBMCs, use the volume indicated above. If there are >107 PBMCs, proportionally increase all reagent volumes and the total volume. - Mix the CD14 microbeads and the cells well in the 1.5 mL microcentrifuge tube and incubate for 15 min in a 4 °C refrigerator. Wash the PBMCs with 1 mL of buffer and centrifuge at 300 × g for 10 min at room temperature. Discard the supernatant completely. Resuspend the cells with 500 µL of the buffer.
NOTE: If there are ≤108 PBMCs, use the volume indicated above. If there are >108 PBMCs, proportionally increase the buffer volume. - Magnetic separation with columns:
- Put the column on the magnetic bead separator, and wash the column with 3 mL of buffer. Add the cell suspension (from step 2.3) to the column.
- Collect the unlabeled cells that pass through the column into a 15 mL centrifuge tube and wash the column with 3 mL of buffer. Wash the column with 3 x 3 mL of buffer. Collect the total effluent in the 15 mL centrifuge tube.
- Place the column in a new 15 mL centrifuge tube. Add 5 mL of buffer to the column. Push the plunger firmly into the column to immediately flush out the magnetically labeled cells into the 15 mL centrifuge tube.
- Centrifuge the magnetically labeled cells at 300 × g for 5 min and remove the supernatant. Resuspend the cells in 500 µL of PBS in a 1.5 mL microcentrifuge tube for use in subsequent transcriptome sequencing.
3. Separation of lymphocyte populations from PBMCs by fluorescently labeled antibody staining and FACS
- Centrifuge the unlabeled cells (step 2.4.2) at 300 × g for 5 min and remove the supernatant. Resuspend the cells in 100 µL of PBS in a 1.5 mL microcentrifuge tube.
- Add 2 µL of each labeled antibody (CD3, CD4, CD8, CD16, CD19, CD56) to the 100 µL of cell suspension (the volumes and conjugated fluorophore information of antibodies are shown in Table 1), incubate on ice for 30 min, and protect from light.
- Wash the cells 2 x by adding 1 mL of PBS and centrifuging at 300 × g for 5 min at room temperature. Resuspend the cells in 500 µL of PBS in the 1.5 mL microcentrifuge tube. Vortex the cell suspension gently before acquiring data on a flow cell sorter cytometer.
4. Flow cytometry parameter setting
- Take 100 µL of the cell suspension (see section 1) in 1.5 mL microcentrifuge tubes as required, and set up a negative control sample, a CD3 single-staining sample, a CD4 single-staining sample, a CD8 single-staining sample, a CD19 single-staining sample, and a CD56/CD16 staining sample.
- Add 2 µL of the corresponding fluorescently labeled antibody per 100 µL of the cell suspension and vortex. Incubate on ice for 30 min in the dark. Centrifuge for 5 min at 300 × g and aspirate the supernatant. Resuspend the pellets with 500 µL of PBS and vortex.
- Commission the sorting stream and delay the droplets using the fluorescent beads as follows:
- Open the cell sorting system, run the power-on program, install the 85 µm nozzle, and open the sorting stream. Set the sorting voltage to 4,500 V, and the Freq to 47.
- Adjust the parameters mainly by adjusting the main flow droplet breakpoint and the droplet delay according to the manufacturer's instructions12. Set up the first droplet breakpoint position (Drop1) to 275, and the Gap to 8 in the Breakoff window. Turn on the Sweet Spot automatic sorting mode to allow the cytometry to automatically determine the droplet amplitude value to stabilize the stream.
- Adjust the droplet delay to 30.31 in the Side Stream window by loading the fluorescent beads, ensuring that the beads achieve a side flow deflection of >99% in either initial or fine tune mode.
- Refer to the gating strategy shown in Figure 1 to perform gating as follows:
- Using a forward scatter-area (FSC-A)/side scatter-area (SSC-A) dot plot, draw the polygon gate (P1) to identify the intact lymphocyte population.
- Using an FSC-A/FSC-height (FSC-H) dot plot, draw the polygon gate (P2) to identify the single cells and exclude doublets (Figure 1A).
- Using a CD19 FITC-A/CD3 PerCP-Cy5.5-A dot plot, draw the rectangular gate (P3) to select CD3+ T cells and CD19+ B cells (Figure 1A,B).
- Using a CD4 APC-Cy7-A/CD8 PE-A dot plot, draw a rectangular gate to select CD4+ T cells and CD8+ T cells (cells with a high fluorescence for these markers, respectively).
- Using a CD56/CD16 APC-A/SSC-A dot plot, draw a rectangular gate to select CD56+/CD16+ NK cells (Figure 1C).
- Adjust instrumental parameters using the negative control sample:
- Install the negative control tube onto the loading port and click Load in the Acquisition Dashboard. Select the Cytometer Settings in the software.
- In the Inspector window, click the Parameters tab, and adjust the voltages of FSC, SSC, and different fluorescent dyes; FSC: 231, SSC: 512, PE: 549, APC: 615, APC-Cyanine 7: 824, FITC: 555, PerCP-Cyanine 5.5: 663.
- Adjust compensation using the single-stained samples13.
- Load the single-stained tubes onto the cytometry sequentially andselect Cytometer Settings in the software. Click the Compensation tab to adjust the compensation.
NOTE: The compensation reference of flow cytometry is shown in Table 2.
- Load the single-stained tubes onto the cytometry sequentially andselect Cytometer Settings in the software. Click the Compensation tab to adjust the compensation.
5. Cell sorting and collecting data via flow cytometry
- Vortex the cell suspension (separated PBMCs according to sections 1–3) briefly to resuspend the cells before loading the tube into the cytometer. Keep the remaining tubes on ice.
- Add 200 µL of FBS to four collection flow tubes to avoid sticking of the sorted cells to the tube wall and place them in the cytometer collection chamber.
- Collect CD3+CD4+ T cells, CD3+CD8+ T cells, CD3−CD19+ B cells, and CD3− CD56+/CD16+ NK cells separately from the sample of a patient with IM in the four flow tubes (Figure 2A).
- Centrifuge the separated cells at 300 × g for 5 min and remove the supernatant. Add 200 µL of RNA isolation reagent to the cells for transcriptome sequencing.
- Separate the immune cell subpopulations of samples from healthy EBV carriers and EBV-uninfected children according to the above steps (Figure 2B, C).
Subscription Required. Please recommend JoVE to your librarian.
Representative Results
Reference of the gating strategy
The gating strategy used to sort the four lymphocyte subpopulations is shown in Figure 1. Briefly, lymphocytes are selected (P1) on a dot plot showing the granulosity (SSC-A) versus size (FSC-A). Then, single cells are selected (P2) on a dot plot showing the size (FSC-A) versus forward scatter (FSC-H), while doublet cells are excluded. CD3+ T cells (P3) and CD19+ B cells (Figure 1B) are selected separately on a dot plot showing the CD3 PerCP-Cy5.5-A versus CD19 FITC-A. CD8+ T cells and CD4+ T cells are selected separately on a dot plot showing CD8 PE-A versus CD4 APC-Cy7-A from P3. CD16+/CD56+ NK cells are selected on a dot plot showing CD56/CD16 APC-A versus SSC-A from P4 (Figure 1C).
The representative results of four cell subpopulations sorted from the samples of patients with IM by the described method are shown in Figure 2A. We also performed cell sorting on samples from healthy EBV carriers and EBV-uninfected children as control groups to confirm the feasibility of this experiment. The representative results of cell subpopulations separated from a healthy EBV carrier's sample are shown in Figure 2B. The representative result of cell subpopulations sorted from the sample of EBV-uninfected children is shown in Figure 2C. As shown in Figure 2, P1 was gated to identify lymphocytes and doublet cells were excluded through P2; P3 was gated to select CD3+ T cells and P5 was gated to select CD19+ B cells; CD3+ CD8+ T cells (P6) and CD3+ CD4+ T cells (P7) were selected separately from P3; CD16+/CD56+ NK cells (P8) were selected from P4. Each of these subpopulations can be individually sorted and collected for downstream experiments. This system was used to analyze gene expression through RNA extraction and transcriptome sequencing.
As reported in Table 3, an increase in CD3+ CD8+ T cells was observed in patients with IM compared to both healthy EBV carriers and EBV-uninfected children (46.5 ± 4.0 vs. 27.0 ± 0.1 and 46.5 ± 4.0 vs. 24.7 ± 2.9, % CD3+ CD8+ T cells per total lymphocytes); Decreased proportions of CD3+ CD4+ T cells and CD19+ B cells were observed in patients with IM compared with healthy EBV carriers and EBV-uninfected children (13.4 ± 1.5 vs. 19.3 ± 1.5 and 13.4 ± 1.5 vs. 23.6 ± 3.2, % CD3+ CD4+ T cells per total lymphocytes; 1.4 ± 0.3 vs. 7.6 ± 0.7 and 1.4 ± 0.3 vs. 9.0 ± 1.5, % CD19+ B cells per total lymphocytes). Decreased proportions of CD16+/CD56+ NK cells were observed in patients with IM compared with EBV-uninfected children (7.5 ± 0.5 vs. 10.7 ± 0.4, % CD16+/CD56+ NK cells per total lymphocytes). These results validated the effectiveness of this sorting protocol and demonstrated that the proportions of lymphocyte subsets are different in patients with IM and EBV-uninfected children.
Figure 1: Overall gating strategy used to sort immune cell subpopulations from PBMCs. (A) The PerCP-Cy5.5 filter was used to separate CD3+ T cells. CD8+ T cells and CD4+ T cells were selected separately on a dot plot showing CD8 PE-A versus CD4 APC-Cy7-A from P3. (B) The FITC filter was used to identify CD19+ B cells. (C) The APC filter was used to separate CD16+/CD56+ NK cells from P4. Abbreviations: PBMCs= peripheral blood mononuclear cells; FSC-A = forward scattering-area; SSC-A = side scattering-area; FSC-H = forward scattering-height; PerCP = peridinin-chrorophyll-protein; PE = phycoerythrin; APC = allophycocyanin; FITC = fluorescein isothiocyanate. Please click here to view a larger version of this figure.
Figure 2: Representative results of four cell subpopulations successfully isolated by the described method. (A) Representative cell sorting figures from the peripheral blood sample of patient with IM. (B) Representative cell sorting figures from the peripheral blood sample of healthy EBV carrier. (C) Representative cell sorting figures from the peripheral blood sample of EBV-uninfected children. P1, dot plot gate to identify lymphocytes; P2, dot plot gate to select single cells; P3, dot plot gate to select CD3+ T cells; P4, dot plot gate to identify CD3- CD19- lymphocytes; P5, dot plot gate to select CD19+ B cells; P6, dot plot gate to select CD3+ CD8+ T cells from P3; P7, dot plot gate to select CD3+ CD4+ T cells from P3; P8, dot plot gate to select CD16+/CD56+ NK cells from P4. Abbreviations: EBV = Epstein–Barr virus; IM = infectious mononucleosis; FSC-A = forward scattering-area; SSC-A = side scattering-area; FSC-H = forward scattering-height; PerCP = peridinin-chrorophyll-protein; PE = phycoerythrin; APC = allophycocyanin; FITC = fluorescein isothiocyanate. Please click here to view a larger version of this figure.
| Antibody Target | Conjugated Fluorophore | Dosage | Clone | Isotype |
| CD3 | PerCP/Cyanine5.5 | 2 µL | SK7 | Mouse IgG1, κ |
| CD4 | APC/Cyanine7 | 2 µL | SK3 | Mouse IgG1, κ |
| CD8 | PE | 2 µL | SK1 | Mouse IgG1, κ |
| CD19 | FITC | 2 µL | HIB19 | Mouse IgG1, κ |
| CD56 | APC | 2 µL | 5.1H11 | Mouse IgG1, κ |
| CD16 | APC | 2 µL | 3G8 | Mouse IgG1, κ |
Table 1: Antibodies used for flow cytometry. Abbreviations: PerCP = peridinin-chrorophyll-protein; PE = phycoerythrin; APC = allophycocyanin; FITC = fluorescein isothiocyanate.
| Compensation reference of flow cytometry (%) | |||||
| PE | APC | APC-Cy7 | FITC | PerCP-Cy5.5 | |
| PE | 100 | 0 | 0 | 0.8 | 4.1 |
| APC | 0 | 100 | 30.1 | 0 | 0.9 |
| APC-Cy7 | 0 | 1.8 | 100 | 0 | 0 |
| FITC | 0 | 0 | 0 | 100 | 0 |
| PerCP-Cy5.5 | 0 | 1.8 | 10 | 0 | 100 |
Table 2: Compensation reference of flow cytometry. Abbreviations: PerCP = peridinin-chrorophyll-protein; PE = phycoerythrin; APC = allophycocyanin; FITC = fluorescein isothiocyanate.
| Proportion of lymphocytes of different subpopulations in total sorted lymphocytes (%) | |||
| lymphocytes subpopulation | IM | healthy EBV carriers | EBV-uninfected children |
| CD3+ T cells | 80.5 ± 1.8 | 70.2 ± 2.3 | 66.1 ± 2.1 |
| CD3+ CD8+ T cells | 46.5 ± 4.0 | 27.0 ± 0.1 | 24.7 ± 2.9 |
| CD3+ CD4+ T cells | 13.4 ± 1.5 | 19.3 ± 1.5 | 23.6 ± 3.2 |
| CD16+/CD56+ NK cells | 7.5 ± 0.5 | 2.2 ± 0.1 | 10.7 ± 0.4 |
| CD3- CD19+ B cells | 1.4 ± 0.3 | 7.6 ± 0.7 | 9.0 ± 1.5 |
Table 3: The proportion of sorted lymphocytes of different groups. Abbreviations: EBV = Epstein–Barr virus; IM = infectious mononucleosis; NK = natural killer.
Subscription Required. Please recommend JoVE to your librarian.
Discussion
This protocol represents an efficient way to sort peripheral blood immune cell subpopulations. In this study, venous blood samples from patients with IM, healthy EBV carriers, and EBV-uninfected children were selected as the research objective. This work using the peripheral blood of patients of IM mainly focuses on analyzing and determining the proportions of different cell subsets through multi-color flow cytometry. Transcriptome sequencing is mainly used for the detection and analysis of a certain subpopulation of lymphocytes that was insufficient for the comprehensive and specific comparisons of the molecular characteristics and functions of different immune cell subpopulations in children with IM at the same disease state. Therefore, sorting out several types of cells from the peripheral blood and performing transcriptome sequencing to compare the differences in the expression genes and functions of these immune cells could provide significant data for the study of the pathogenesis of IM.
FACS sorting has the additional benefit of being able to process live, fractionated cells for further in vitro or in vivo experiments14. Maintaining the cell viability is vital for subsequent experiments. We have optimized the sorting step to improve cell viability in this protocol-experimental manipulations have been performed on ice or in a 4 °C refrigerator. Proper centrifugation speed and time are also critical for cell isolation. The yield of sorted cells is also the main constraint in this method, and the use of FBS-coated tubes during sorting can greatly reduce the loss of cells that adhere to the tubes. Providing the proper settings for the FACS sorter can improve the overall efficiency of the sorting by avoiding cell blockage or cross-contamination in the collection tube. Through the optimization of experimental steps and settings, this protocol can be extrapolated to the sorting of other immune cells by replacing magnetic or fluorescent labels. However, due to the specificity of the children's samples (low blood collection volume), we only investigated the major populations of immune cells (monocytes, CD4+ T cells, CD8+ T cells, B cells, and NK cells) without proceeding to sort subpopulations due to the restriction of the flow sorting channel. This study demonstrated that peripheral blood samples from immunocompetent children and samples from IM could successfully sort out these five groups of immune cells; however, the blood samples of patients with hematological malignancies (e.g., leukemia, lymphoma), lymphoproliferative disorders (e.g., posttransplant lymphoproliferative disorders, CAEBV), or primary immunodeficiency/acquired immune deficiency syndrome may not be successfully sorted according to this protocol.
IM is considered a self-limiting disease, and immune cells such as γδ T cells, NKT cells, and NK cells play a significant role in the antiviral immune response15. EBV-specific CD8+ T cells are largely differentiated toward an effector phenotype10,16, and there is contraction of late effector memory and effector cells from IM to convalescence17. Meanwhile, NK cells in IM appear to be functionally defective, including lack of cell activation10, loss of activating receptor signaling, and degranulation18. Some studies have found that CD4+ T cells can not only assist CD8+ T cells to kill and eliminate EBV-infected B cells but also inhibit the proliferation of B cells by secreting cytokines and even directly play a killing role during EBV infection19,20. As shown in this study, an increased proportion of CD3+ CD8+ T cells was observed in patients with IM compared to both healthy EBV carriers and EBV-uninfected children. In contrast, decreased proportions of CD3+ CD4+ T cells, CD19+ B cells, and CD16+/CD56+ NK cells were observed in patients with IM compared with EBV-uninfected children. However, the function and gene expression of these different subtypes of immune cells in the same disease state of IM remain unclear. Further analysis of the gene expression profiles of specific immune cell subsets in IM can help to gain insight into the pathogenic mechanism of IM.
We provide a strategy that combines immunomagnetic bead sorting and FACS to isolate and analyze defined immune cell subpopulations in PBMCs. Monocytes are separated first using CD14 microbeads, and the remaining PBMCs are stained with corresponding fluorescently labeled antibodies to sort CD4+ T cells, CD8+ T cells, B cells, and NK cells through FACS. We further used these sorted cells for RNA extraction and transcriptome sequencing to characterize the function and gene expression of different immune cells in the immunopathology of IM. The purity and yield of the sorted cells was generally sufficient to conduct gene expression studies (data not shown). Therefore, the sorting method of separate immune cell subpopulations can be used to further explore EBV-associated lymphoproliferative disorders such as CAEBV, post-transplant lymphoproliferative disorder to detect pathogenic genes, pathogenic proteins, and potential therapeutic targets.
Subscription Required. Please recommend JoVE to your librarian.
Disclosures
The authors declare no conflicts of interest.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (82002130), Beijing Natural Science Foundation (7222059) and the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-026).
Materials
| Name | Company | Catalog Number | Comments |
| APC anti-human CD16 | Biolegend | 302012 | Fluorescent antibody |
| APC anti-human CD56 (NCAM) | Biolegend | 362504 | Fluorescent antibody |
| APC/Cyanine7 anti-human CD4 | Biolegend | 344616 | Fluorescent antibody |
| Automated cell counter | BIO RAD | TC20 | Cell count |
| BD FACSAria fluorescence-activated flow cell sorter-cytometer (BD FACSAria II) | Becton, Dickinson and Company | 644832 | Cell sort |
| CD14 MicroBeads, human | Miltenyi Biotec | 130-050-201 | microbeads |
| Cell ctng slides | BIO RAD | 1450016 | Cell count |
| Centrifuge tubes | Falcon | 35209715 | 15 mL centrifuge tube |
| EDTA (≥99%, BioPremium) | Beyotime | ST1303 | EDTA |
| Ethylene diamine tetra acetic acid (EDTA) anticoagulant tubes | Becton, Dickinson and Company | 367862 | EDTA anticoagulant tubes |
| FITC anti-human CD19 | Biolegend | 302206 | Fluorescent antibody |
| Gibco Fetal Bovine Serum | Thermo Fisher Scientific | 16000-044 | Fetal Bovine Serum |
| High-speed centrifuge | Sigma | 3K15 | Cell centrifugation for 15 mL centrifuge tube |
| High-speed centrifuge | Eppendorf | 5424R | Cell centrifugation for 1.5 mL Eppendorf (EP) tube |
| Human lymphocyte separation medium | Dakewe | DKW-KLSH-0100 | Ficoll-Paque |
| LS Separation columns | Miltenyi Biotec | 130-042-401 | Separation columns |
| Microcentrifuge tubes | Axygen | MCT-150-C | 1.5 mL microcentrifuge tube |
| MidiMACS Separator | Miltenyi Biotec | 130-042-302 | Magnetic bead separator |
| PE anti-human CD8 | Biolegend | 344706 | Fluorescent antibody |
| PerCP/Cyanine5.5 anti-human CD3 | Biolegend | 344808 | Fluorescent antibody |
| Phosphate Buffered Saline (PBS) | BI | 02-024-1ACS | PBS |
| Polystyrene round bottom tubes | Falcon | 352235 | 5 mL tube for FACS flow cytometer |
| TRIzol reagent | Ambion | 15596024 | Lyse cells for RNA extraction |
| Trypan Blue Staining Cell Viability Assay Kit | Beyotime | C0011 | Trypan Blue Staining |
References
- Kwok, H., Chiang, A. K. From conventional to next generation sequencing of Epstein-Barr virus genomes. Viruses. 8 (3), 60 (2016).
- Bu, W., et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity. 50 (5), 1305-1316 (2019).
- Balfour, H. H., et al. Behavioral, virology, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. Journal of Infectious Diseases. 207 (1), 80-88 (2013).
- Luzuriaga, K., Sullivan, J. L. Infectious mononucleosis. New England Journal of Medicine. 362 (21), 1993-2000 (2010).
- Fujiwara, S., et al. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatrics International. 56 (2), 159-166 (2014).
- Tsao, S. W., Tsang, C. M., Lo, K. W. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 372 (1732), 20160270 (2017).
- Zhong, H., et al. Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein-Barr virus infection. Scientific Reports. 7 (1), 17775 (2017).
- Fedyanina, O. S., et al. The nature and clinical significance of atypical mononuclear cells in infectious mononucleosis caused by the Epstein-Barr virus in children. Journal of Infectious Diseases. 223 (10), 1699-1706 (2021).
- Al Tabaa, Y., et al. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis. Journal of Clinical Virology. 52 (1), 33-37 (2011).
- M, A., et al. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation. Immunobiology. 225 (3), 151907 (2020).
- Greenough, T. C., et al. A gene expression signature that correlates with CD8+ T cell expansion in acute EBV infection. Journal of Immunology. 195 (9), 4185-4197 (2015).
- Xia, Y., Gao, Y., Wang, B., Zhang, H., Zhang, Q. Optimizing the method of cell separation from bile of patients with cholangiocarcinoma for flow cytometry. Gastroenterology Research and Practice. , 5436961 (2019).
- Maecker, H. T., Trotter, J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry Part A. 69 (9), 1037-1042 (2006).
- Byford, E., Carr, M., Pinon, L., Ahearne, M. J., Wagner, S. D. Isolation of CD4+ T-cells and analysis of circulating T-follicular helper (cTfh) cell subsets from peripheral blood using 6-color flow cytometry. Journal of Visualized Experiments. (143), e58431 (2019).
- Djaoud, Z., et al. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and gammadelta T cells. Journal of Experimental Medicine. 214 (6), 1827-1841 (2017).
- Nakid-Cordero, C., Baron, M., Guihot, A., Vieillard, V. Natural killer cells in post-transplant lymphoproliferative disorders. Cancers. 13 (8), 1836 (2021).
- Forrest, C., Hislop, A. D., Rickinson, A. B., Zuo, J. Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection. PLoS Pathogens. 14 (9), 1007110 (2018).
- Zamai, L., et al. Understanding the Synergy of NKp46 and co-activating signals in various NK cell subpopulations: paving the way for more successful NK-cell-based immunotherapy. Cells. 9 (3), 753 (2020).
- Lam, J. K. P., et al. Emergence of CD4+ and CD8+ polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection. Frontiers In Microbiology. 9, 416 (2018).
- Choi, I. K., et al. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4(+) and CD8(+) T cell responses. Proceedings of the National Academy of Sciences. 115 (4), 686-695 (2018).
